Oral Infection Caused by Stenotrophomonas maltophilia: A Rare Presentation of an Emerging Opportunistic Pathogen

Marcelo Prates, Fernando Fernandes, Francisco Proença, Yashad Mussá, Ana Tavares, André Pereira, Marcelo Prates, Fernando Fernandes, Francisco Proença, Yashad Mussá, Ana Tavares, André Pereira

Abstract

Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic pathogen with an increasing incidence of nosocomial and community-acquired infection cases, mainly in immunocompromised individuals. Oral cavity infections are rare. To learn more about this infection, a case of oral cavity infection caused by S. maltophilia in an immunosuppressed patient under ventilatory therapy has been presented. The patient presented with multiple nonpainful erosive lesions of the tongue, palate, and oral mucosa. A smear of the oral lesions was performed that revealed the presence of S. maltophilia and Candida albicans, and the patient was treated with fluconazole and sulfamethoxazole associated with trimethoprim in accordance with the antimicrobial susceptibility testing. After 14 days of antibiotic therapy, there were almost no signs of the previous lesions.

Conflict of interest statement

The authors declare no conflicts of interest.

Copyright © 2020 Marcelo Prates et al.

Figures

Figure 1
Figure 1
Tongue (a) and palatal (b) lesions when first observed.
Figure 2
Figure 2
Tongue lesions 6 days after beginning directed antibiotic therapy.
Figure 3
Figure 3
Tongue (a) and palate (b) at the discharge day after 14 days of directed antibiotic therapy.

References

    1. Brooke J. S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clinical Microbiology Reviews. 2012;25(1):2–41. doi: 10.1128/CMR.00019-11.
    1. De Mauri A., Torreggiani M., Chiarinotti D., Andreoni S., Molinari G., De Leo M. Stenotrophomonas maltophilia: an emerging pathogen in dialysis units. Journal of Medical Microbiology. 2014;63(Pt_11):1407–1410. doi: 10.1099/jmm.0.076513-0.
    1. Falagas M. E., Kastoris A. C., Vouloumanou E. K., Rafailidis P. I., Kapaskelis A. M., Dimopoulos G. Attributable mortality of Stenotrophomonas maltophiliainfections: a systematic review of the literature. Future Microbiology. 2009;4(9):1103–1109. doi: 10.2217/fmb.09.84.
    1. Looney W. J., Narita M., Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. The Lancet Infectious Diseases. 2009;9(5):312–323. doi: 10.1016/S1473-3099(09)70083-0.
    1. Samonis G., Karageorgopoulos D. E., Maraki S., et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One. 2012;7(5) doi: 10.1371/journal.pone.0037375.e37375
    1. Osawa K., Shigemura K., Kitagawa K., Tokimatsu I., Fujisawa M. Risk factors for death from Stenotrophomonas maltophilia bacteremia. Journal of Infection and Chemotherapy. 2018;24(8):632–636. doi: 10.1016/j.jiac.2018.03.011.
    1. Calza L., Manfredi R., Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection. 2003;31(3):155–161. doi: 10.1007/s15010-003-3113-6.
    1. Apisarnthanarak A., Mayfield J. L., Garison T., et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infection Control & Hospital Epidemiology. 2003;24(4):269–274. doi: 10.1086/502197.
    1. Lai C. H., Chi C. Y., Chen H. P., et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. Journal of Microbiology, Immunology, and Infection = Wei Mian Yu gan Ran Za Zhi. 2004;37(37):350–358.
    1. Denton M., Kerr K. G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical Microbiology Reviews. 1998;11(1):57–80. doi: 10.1128/cmr.11.1.57.
    1. Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. Journal of Hospital Infection. 2004;57(1):1–7. doi: 10.1016/j.jhin.2004.01.033.
    1. Friedman N. D., Korman T. M., Fairley C. K., Franklin J. C., Spelman D. W. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. Journal of Infection. 2002;45(1):47–53. doi: 10.1053/jinf.2002.0978.
    1. Subhani S., Patnaik A. N., Barik R., Nemani L. Infective endocarditis caused by Stenotrophomonas maltophilia: a report of two cases and review of literature. Indian Heart Journal. 2016;68(2):S267–S270. doi: 10.1016/j.ihj.2015.07.048.
    1. Morte E., Tolmos M., Halperin A., Morosini M. I., Cantón R., Hermida J. M. Early prosthetic endocarditis caused by Stenotrophomonas maltophilia. Médecine et Maladies Infectieuses. 2018;48(8):543–546. doi: 10.1016/j.medmal.2018.09.004.
    1. Crum N. F., Utz G. C., Wallace M. R. Stenotrophomonas maltophilia endocarditis. Scandinavian Journal of Infectious Diseases. 2002;34(12):925–927. doi: 10.1080/0036554021000026977.
    1. Padilla D., Cubo T., Dolores Romero M., et al. Infección nosocomial por Stenotrophomonas maltophilia en enfermos intervenidos quirúrgicamente. Enfermedades Infecciosas Y Microbiología Clínica. 2002;20(4):189–190. doi: 10.1016/s0213-005x(02)72786-9.
    1. Platsouka E., Routsi C., Paniara O., Roussos C., Dimitriadou E., Chalkis A. Stenotrophomonas maltophilia meningitis, bacteremia and respiratory infection. Scandinavian Journal of Infectious Diseases. 2002;34(5):391–392. doi: 10.1080/00365540110080520.
    1. Sakhnini E., Weissmann A., Oren I. Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. The American Journal of the Medical Sciences. 2002;323(5):269–272. doi: 10.1097/00000441-200205000-00008.
    1. Moser C., Jonsson V., Thomsen K., Albrectsen J., Hansen M. M., Prag J. Subcutaneous lesions and bacteraemia due to Stenotrophomonas maltophilia in three leukaemic patients with neutropenia. British Journal of Dermatology. 1997;136(6):949–952. doi: 10.1046/j.1365-2133.1997.d01-200.x.
    1. Burns R. L., Lowe L. Xanthomonas maltophilia infection presenting as erythematous nodules. Journal of the American Academy of Dermatology. 1997;37(5):836–838. doi: 10.1016/s0190-9622(97)80006-0.
    1. Vartivarian S. E., Papadakis K. A., Anaissie E. J. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Archives of Internal Medicine. 1996;156(4):433–435. doi: 10.1001/archinte.156.4.433.
    1. Fujita J., Yamadori I., Xu G., et al. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respiratory Medicine. 1996;90(1):35–38. doi: 10.1016/s0954-6111(96)90242-5.
    1. Taylor G., McKenzie M., Buchanan-Chell M., Perry D., Chui L., Dasgupta M. Peritonitis due to Stenotrophomonas maltophilia in patients undergoing chronic peritoneal dialysis. Peritoneal Dialysis International. 1999;19(3):259–262.
    1. Khan I. A., Mehta N. J. Stenotrophomonas maltophilia endocarditis: a systematic review. Angiology. 2002;53(1):49–55. doi: 10.1177/000331970205300107.
    1. Wang W. S., Liu C. P., Lee C. M., Huang F. Y. Stenotrophomonas maltophilia bacteremia in adults: four years’ experience in a medical center in northern Taiwan. Journal of Microbiology, Immunology and Infection. 2004;37(6):359–365.
    1. Gautam V., Kumar S., Kaur P., et al. Antimicrobial susceptibility pattern of Burkholderia cepacia complex & Stenotrophomonas maltophilia over six years (2007–2012) Indian Journal of Medical Research. 2015;142(4):492–494. doi: 10.4103/0971-5916.169225.
    1. Nicodemo A. C., Paez J. I. G. Antimicrobial therapy for Stenotrophomonas maltophilia infections. European Journal of Clinical Microbiology & Infectious Diseases. 2007;26(4):229–237. doi: 10.1007/s10096-007-0279-3.
    1. Singhal L., Kaur P., Gautam V. Stenotrophomonas maltophilia: from trivial to grievous. Indian Journal of Medical Microbiology. 2017;35(4):469–479. doi: 10.4103/ijmm.IJMM_16_430.
    1. Abbott I. J., Slavin M. A., Turnidge J. D., Thursky K. A., Worth L. J. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Review of Anti-Infective Therapy. 2011;9(4):471–488. doi: 10.1586/eri.11.24.
    1. Brooke J. S. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Review of Anti-Infective Therapy. 2014;12(1):1–4. doi: 10.1586/14787210.2014.864553.
    1. Huedo P., Coves X., Daura X., Gibert I., Yero D. Quorum sensing signaling and quenching in the multidrug-resistant pathogen Stenotrophomonas maltophilia. Frontiers in Cellular and Infection. 2018;8(122) doi: 10.3389/fcimb.2018.00122.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe